Skip to main content

Table 4 Adjusted Cox proportional hazard model for treatment discontinuation

From: Treatment persistence of biologics among patients with psoriatic arthritis

 

HR

95.0% CI

Lower

Upper

Female vs. male

1.249

1.134

1.376

Age 30–39 (compared to 18–29)

0.972

0.785

1.204

Age 40–49

1.000

0.810

1.234

Age 50–59

1.032

0.836

1.273

Age 60–69

0.945

0.758

1.178

Age > 70

1.061

0.812

1.387

SES—medium

0.898

0.798

1.011

SES—high

0.918

0.805

1.048

Ethnicity—Arab

1.136

0.972

1.328

Ethnicity—Jewish

0.913

0.693

1.203

Charlson comorbidity index

1.004

0.973

1.035

BMI_thin

1.146

0.833

1.577

BMI_overweight

1.082

0.952

1.228

BMI_obese

1.126

0.993

1.278

Smokers

1.109

1.008

1.219

Concomitant MTX

0.830

0.737

0.933

Concomitant cDMARDs

0.958

0.811

1.131

MTX use before

0.891

0.788

1.008

cDMARDs use before

1.027

0.931

1.134

Concurrent GC

0.569

0.515

0.629

Rx line2 vs. line1

1.263

1.117

1.427

Rx line3 vs. line1

1.296

1.119

1.500

Rx line4 vs. line1

1.590

1.382

1.829

Start of biologic 2012 vs. 2018

1.657

1.339

2.051

Start of biologic 2013 vs. 2018

1.526

1.234

1.887

Start of biologic 2014 vs. 2018

1.484

1.204

1.829

Start of biologic 2015 vs. 2018

1.521

1.233

1.878

Start of biologic 2016 vs. 2018

1.697

1.393

2.066

Start of biologic 2017 vs.2018

1.410

1.157

1.719

  1. BMI body mass index, cDMARDs conventional disease-modifying anti-rheumatic drugs, GC glucocorticosteroids, MTX methotrexate, Rx treatment, SES socioeconomic status